5[2]Naghavi M,libby P,Falk E,et al.From Vulnerable plaque to vulnerable patient:a call for new definitions and risk assessment strategies:part Ⅰ[J].Circulation,2003,108:1664-1672.
6[3]Naghavi M,libby P,Falk E,et al.From Vulnerable plaque to vulnerable patient:a call for nwe definitions and risk assessment strategies:part Ⅱ[J].circulation,2003,108:1772-1778.
7[4]Rauch U,Osende JI,Chesebro JH,et al.statins and cardiovascular disease:the multiple effects of lipid-lowering therapy by statins[J].Atherosclerosis,2000,153:181-189.
8[5]Berk BB,Weintraub WS,Alexander RW.Elevation of C-reactive protein in "active"coronary disease[J].Am J Cardiol,1990,65:168-172.
9[6]Ballou SP,Cleveland RP.Binding of human C-reactive protein to monocytes:analysis by flow cytometry[J].Clin Exp lmmunol.1991,84:329-335.
10Dahlen GH.Lp(a)lipoprotein,IgG,IgA IgM and antibodies to Chlamydia pneumoniae and HLA Ⅱgenotype in early coronary artery disease[J].Atheroslerosis,1995.114(2):165.
